Browse the corpus

Indomethacin is a potent nonsteroidal anti-inflammatory drug with broad applications. The drug inhibits prostaglandin synthesis produced by cyclooxygenase enzymes, which are critical mediators of inflammation, fever, and pain. Indomethacin is approved by the US Food and Drug Administration (FDA) to manage acute pain, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis, gouty arthritis, and patent ductus arteriosus. Clinicians often use indomethacin as a supportive treatment within a medication regimen. This activity focuses on the indications, contraindications, and administration methods of indomethacin as a valuable therapeutic agent, as well as its key factors, such as off-label uses, dosing, pharmacokinetics, monitoring, and relevant interactions. This activity underscores the crucial role of interprofessional healthcare teams in monitoring indomethacin therapy by tailoring treatment plans to individual patient needs depending on pain acuity, making informed decisions, and optimizing dosage regimens while minimizing adverse reactions. This evidence-based approach improves patient outcomes in inflammatory conditions treated with indomethacin. Objectives: Identify the specific indications for indomethacin therapy in different inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis, and patent ductus arteriosus. Implement appropriate dosing regimens of indomethacin based on the patient's condition, considering factors such as pain severity, renal function, and age. Apply evidence-based guidelines and clinical recommendations for using indomethacin in specific patient populations, including pediatric, geriatric, and pregnant individuals. Collaborate with other healthcare providers to optimize indomethacin therapy and coordinate comprehensive patient care. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Indomethacin toxicity is rare, with only a few cases reported in the literature. Documented cases have demonstrated symptoms such as headache, tinnitus, dizziness, lethargy, drowsiness, confusion, disorientation, restlessness, and acute kidney injury secondary to indomethacin toxicity.[54][55] Management of Overdose Healthcare providers should offer patients supportive and symptomatic care following indomethacin dosage. A specific antidote for indomethacin toxicity is not available. For adult patients, administering 60 to 100 g of activated charcoal should be considered to decrease the absorption of NSAIDs from the upper gastrointestinal tract. Osmotic cathartics may be used in symptomatic patients observed within 4 hours of overdose or in patients who ingested 5 to 10 times the recommended dosage of indomethacin. The local poison control center should be contacted for detailed information on the treatment protocol.

All healthcare personnel should operate as an interprofessional team and understand the risks of indomethacin treatment. Prescribers should tailor the regimen to the lowest effective dose for the shortest duration possible. Clinicians should avoid NSAIDs in patients with peptic ulcers, those who have undergone CABG, and those in the third trimester of pregnancy. Nurses must exercise caution before administering medications and counseling patients on identifying therapeutic success or adverse reactions. Prescribers should periodically monitor patients with a history of cardiovascular events, hepatotoxicity, and severe gastrointestinal bleeding and renal impairment to prevent potential adverse events. Pharmacists should verify the dose, perform medication reconciliation, check for drug interactions, educate patients, and report any concerns to the clinician. The critical care team should rapidly stabilize patients experiencing an indomethacin overdose and consult a medical toxicologist if necessary. An interprofessional team approach, with open communication between clinicians, specialists, nurses, and pharmacists regarding the therapeutic goals and potential adverse reactions to the indomethacin regimen, can lead to optimal patient outcomes.[56][57]